Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
List view / Grid view
Filter the results
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
By removing two kinds of macrophages in mice, researchers showed that ovarian tumours in mice were reduced in size and stopped spreading.
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Researchers have shown that natural killer (NK) cells work best as an immunotherapy when in an early stage of development, so could be manufactured from pluripotent stem cells.
Researchers have found that there is less calmodulin binding to ion channels in the T cells from cancer patients, presenting a new immunotherapeutic target.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
A new study conducted in Israel suggests that T cells’ ability to destroy skin cancer increases in the absence of T-cell regulators called SLAMF6.
Researchers have discovered that a small molecule can help some T cells combat tumours during PD-1 blockade immunotherapy in mice.
A study has shown that in mice, the GKT137831 drug makes tumours more sensitive to immunotherapy, so could be used to improve cancer treatments.
New T-cell discovery could lead to treatments for both bacterial infections and autoimmune conditions
A novel highly activated form of T cells could be suppressed to treat autoimmune conditions and activated in treating bacterial infections.